MapLight Therapeutics/$MPLT

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About MapLight Therapeutics

MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.

Ticker

$MPLT
Sector
Health
Primary listing
NASDAQ

Employees

109
Headquarters
Redwood City, United States
Website
www.maplightrx.com

MPLT Metrics

BasicAdvanced
$681M
-
-$121.50
-
-

Bulls say / Bears say

MapLight closed an oversubscribed $372.5 million Series D in July 2025, with Forbion and Goldman Sachs Alternatives as lead investors. This gives the company plenty of capital to advance both clinical and preclinical projects. (Reuters)
During its IPO in October 2025, MapLight raised $250.8 million at $17 a share, reaching a valuation up to $704.3 million. The offering came as biotech IPO activity rebounded, reflecting investor enthusiasm for its central nervous system platform. (Reuters)
MapLight’s pipeline is diversified, with ML-007C-MA and ML-004 in Phase 2 for schizophrenia, Alzheimer’s-related psychosis, and autism spectrum disorder, as well as preclinical programs for Parkinson’s and hyperactivity. This breadth provides multiple near-term clinical catalysts. (Reuters)
MapLight reported a net loss of $52.2 million for the first half of 2025, up from $37.3 million a year earlier, highlighting continued high R&D expenses without any commercial revenue to offset costs. (Reuters)
The company’s SEC filings show its IND application for ML-007C-MA was placed on clinical hold by the FDA in May 2024 due to nonclinical findings, pointing to potential regulatory hurdles that could delay key Phase 2 studies. (StreetInsider)
With no approved products and a post-IPO valuation near $704.3 million, MapLight is highly exposed to the binary risk of mid-stage clinical trials and uncertain regulatory approvals, which could significantly increase share volatility. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2025.

MPLT Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MPLT News

AllArticlesVideos
MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut

MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut

Reuters2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MPLT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs